Literature DB >> 3008760

Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.

J A Houghton, K D Weiss, L G Williams, P M Torrance, P J Houghton.   

Abstract

5-Fluorouracil (FUra) has been administered to mice bearing xenografts of human colon adenocarcinomas. In two tumor lines, HxGC3 and HxVRC5, intrinsically resistant to FUra, 2'-deoxyuridylate (dUMP) accumulated 13.4- and 23.9-fold above basal levels. In HxELC2 xenografts, which demonstrated some sensitivity to FUra, there was a decrease in dUMP concentration after drug administration. Maximal intratumor levels of 5-fluoro-2'-deoxyuridylate (FdUMP) were found at 1 hr, but decreased in all tumor lines by 4 hr after administration of FUra. Data derived in tumor cytosols suggested that FdUMP levels in situ were not rate-limiting for formation of covalent ternary complex, but that accumulation of dUMP would retard the rate of complex formation. Subsequent to administration of FUra, thymidylate synthase activity was reduced greater than 75% in all tumors, but it recovered rapidly in tumors resistant to FUra. In addition, the pretreatment level of activity of thymidylate synthase was 12.7-fold greater in HxVRC5 tumors than in HxELC2 tumors. This elevated activity in HxVRC5 tumors appears not to be a consequence of gene amplification. Formation of FdUMP or the accumulation of dUMP did not correlate with the activity of phosphatases measured at pH 5.8 or pH 9.2 in each tumor line. Further, inhibition of phosphatase activity did not alter, significantly, the net rate of dissociation of the FdUMP-thymidylate synthase-[6R]-CH2-H4PteGlu complex.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3008760     DOI: 10.1016/0006-2952(86)90281-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency.

Authors:  P J Houghton; G S Germain; B J Hazelton; J W Pennington; J A Houghton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

Review 2.  Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.

Authors:  P J Houghton; J A Houghton; B J Hazelton; S Radparvar
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

3.  Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum.

Authors:  P K Rathod; N P Leffers; R D Young
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

4.  Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair.

Authors:  A D Bulgar; L D Weeks; Y Miao; S Yang; Y Xu; C Guo; S Markowitz; N Oleinick; S L Gerson; L Liu
Journal:  Cell Death Dis       Date:  2012-01-12       Impact factor: 8.469

5.  Kinetic analysis of 5-fluorouracil action against various cancer cells.

Authors:  M Inaba; J Mitsuhashi; S Ozawa
Journal:  Jpn J Cancer Res       Date:  1990-10

6.  Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; T Morikage; Y Fujiwara; N Saijo
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

7.  Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells.

Authors:  M Inaba; J Mitsuhashi; H Sawada; N Miike; Y Naoe; A Daimon; K Koizumi; H Tsujimoto; M Fukushima
Journal:  Jpn J Cancer Res       Date:  1996-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.